ArticleJournal of neural transmission (Vienna, Austria : 1996)2025
An efficient ranking-based ensembled multiclassifier for neurodegenerative diseases classification using deep learning.
Article in Journal of neural transmission (Vienna, Austria : 1996), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Computer-Aided Decision Support Systems of Alzheimer's Disease Diagnosis - A Systematic Review.Current medical imaging · 2025Pooled it
- Deep learning-based cognitive impairment brain imaging analysis: New methods, new technologies, and new paradigms.Neural regeneration research · 2026Article
- The Synergistic Neuroprotective Effect of Honokiol and Magnolol Against Amyloid-β and MPPInternational journal of molecular sciences · 2026Article
- Advancing biomedical data analytics using explainable neural network-based learning model for progressive neurodegenerative disorder diagnosis.Scientific reports · 2026Article
- Design of a deep learning prediction model for Alzheimer's and Parkinson's Disease using MRI images.Frontiers in artificial intelligence · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegenerative diseases are group of debilitating and progressive disorders that primarily affect the structure and functions of nervous system, leading to gradual loss of neurons and subsequent decline in cognitive, and behavioral activities. The two frequent diseases affecting the world's significant population falling in the above category are Alzheimer's disease (AD) and Parkinson's disease (PD). These disorders substantially impact the quality of life and burden healthcare systems and society. The demographic characteristics, and machine learning approaches have now been employed to diagnose these illnesses; however, they possess accuracy limitations. Therefore, the authors have developed ranking-based ensemble approach based on the weighted strategy of deep learning classifiers. The whole modeling procedure of the proposed approach incorporates three phases. In phase I, preprocessing techniques are applied to clean the noise in datasets to make it standardized according to deep learning models as it significantly impacts their performance. In phase II, five deep learning models are selected for classification and calculation of prediction results. In phase III, a ranking-based ensemble approach is proposed to ensemble the results of the five models after calculating the ranks and weights of them. In addition, the Magnetic Resonance Imaging (MRI) datasets named Alzheimer's Disease Neuroimaging Initiative (ADNI) for AD classification and Parkinson's Progressive Marker Initiative (PPMI) for PD classification are selected to validate the proposed approach. Furthermore, the proposed method achieved the classification accuracy on AD- Cognitive Normals (CN) at 97.89%, AD- Mild Cognitive Impairment (MCI) at 99.33% and CN-MCI at 99.44% and on PD-CN at 99.22%, PD- Scans Without Evidence of Dopaminergic Effect (SWEDD) at 97.56% and CN-SWEDD at 98.22% respectively. Also, the multi-class classification shows the promising accuracy of 97.18% for AD and 97.85% for PD for the proposed framework. The findings of the study show that the proposed deep learning-based ensemble technique is competitive for AD and PD prediction in both multiclass and binary class classification. Furthermore, the proposed approach enhances generalization performance in diagnosing neurodegenerative diseases and performs better than existing approaches.
Indexed as
Identifiers
39249515What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.